ArticleVaccines2022

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901.

Josue Antonio Estrada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.